Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase Ⅱa exploratory trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase Ⅱa exploratory trial

Published:2023 Issue: Volume: Page:
ISSN:2186-3342
Container-title:Bioscience of Microbiota, Food and Health
language:en
Short-container-title:

Author:

OHKUBO Hidenori¹,KESSOKU Takaomi¹,TANAKA Kosuke¹,TAKAHASHI Kota¹,TAKATSU Tomohiro¹,YOSHIHARA Tsutomu¹,MISAWA Noboru¹,ASHIKARI Keiichi¹,FUYUKI Akiko¹,KATO Shingo¹,HIGURASHI Takuma¹,HOSONO Kunihiro¹,YONEDA Masato¹,MISUMI Toshihiro²,SHINODA Satoru²,STANGHELLINI Vincenzo³,NAKAJIMA Atsushi¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Japan

2. Department of Biostatistics, Yokohama City University School of Medicine, Japan

3. IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Italy

Publisher

BMFH Press

Subject

Gastroenterology,Applied Microbiology and Biotechnology,Immunology,Microbiology,Food Science

Link

https://www.jstage.jst.go.jp/article/bmfh/advpub/0/advpub_2023-080/_pdf

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP